AbbVie Inc.(ABBV) Unit Expands Skin Solution Availability amid $5.2B Opportunity

AbbVie Inc. (NYSE:ABBV) is one of the best conservative stocks to buy now. On September 23, the company’s subsidiary, Allergan Aesthetics, announced the rollout of SKINVIVE by JUVÉDERM in 35 additional markets.

With the expansion, the skin care solution is now available in 57 global markets. The expansion comes amid growing market demand for solutions that can enhance facial skin quality. It also positions AbbVie to pursue opportunities in the skin quality market, valued at $5.2 billion.

Additionally, the expansion aligns with AbbVie’s push to diversify its revenue streams beyond Humira, which is facing significant pressure from biosimilar competition.

“As we observe a shift in consumer behavior towards skin health-focused solutions, we’re committed to evolving our injectable portfolio. Through introducing innovative injection techniques, new treatment approaches with AA Signature™, and strategic product launches worldwide, our mission is to help empower practitioners deliver the best possible results for their patients,” said Mark Wilson, SVP, International Allergan Aesthetics.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines and solutions for complex health issues, with a focus on therapeutic areas such as immunology, oncology, and virology.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Performing Penny Stocks to Buy Now and 11 Best Healthcare Penny Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.